252 related articles for article (PubMed ID: 30027841)
1. Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses.
Grzegorzewska AE
Curr Med Chem; 2019; 26(25):4832-4851. PubMed ID: 30027841
[TBL] [Abstract][Full Text] [Related]
2. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
[TBL] [Abstract][Full Text] [Related]
3. Correlations of indoleamine 2,3-dioxygenase, interferon-λ3, and anti-HBs antibodies in hemodialysis patients.
Grzegorzewska AE; Winnicka H; Warchoł W; Mostowska A; Jagodziński PP
Vaccine; 2018 Jul; 36(30):4454-4461. PubMed ID: 29935858
[TBL] [Abstract][Full Text] [Related]
4. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
[TBL] [Abstract][Full Text] [Related]
5. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
[TBL] [Abstract][Full Text] [Related]
6. Absence of interferon-λ 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection.
Waldenström J; Kåberg M; Alanko Blomé M; Widell A; Björkman P; Nilsson S; Hammarberg A; Weiland O; Nyström K; Lagging M
Scand J Gastroenterol; 2021 Jul; 56(7):855-861. PubMed ID: 34034600
[TBL] [Abstract][Full Text] [Related]
7. Circulating Interferon-
Grzegorzewska AE; Świderska MK; Mostowska A; Jagodziński PP
Biomed Res Int; 2017; 2017():3713025. PubMed ID: 29226133
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study.
Grzegorzewska AE; Mostowska A; Świderska MK; Marcinkowski W; Stolarek I; Figlerowicz M; Jagodziński PP
BMC Infect Dis; 2021 Jan; 21(1):102. PubMed ID: 33482747
[TBL] [Abstract][Full Text] [Related]
9. Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden.
Lu YF; Goldstein DB; Urban TJ; Bradrick SS
Virology; 2015 Feb; 476():334-340. PubMed ID: 25577150
[TBL] [Abstract][Full Text] [Related]
10. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection.
Bhushan A; Ghosh S; Bhattacharjee S; Chinnaswamy S
J Interferon Cytokine Res; 2017 Aug; 37(8):369-382. PubMed ID: 28727946
[TBL] [Abstract][Full Text] [Related]
11. Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression.
Ferraris P; Chandra PK; Panigrahi R; Aboulnasr F; Chava S; Kurt R; Pawlotsky JM; Wilkens L; Osterlund P; Hartmann R; Balart LA; Wu T; Dash S
Am J Pathol; 2016 Apr; 186(4):938-51. PubMed ID: 26896692
[TBL] [Abstract][Full Text] [Related]
12. Identifying causal variants at the interferon lambda locus in case-control studies: Utilizing non-synonymous variant rs117648444 to probe the role of IFN-λ4.
Bhushan A; Chinnaswamy S
Gene; 2018 Jul; 664():168-180. PubMed ID: 29705128
[TBL] [Abstract][Full Text] [Related]
13. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Interferon-λ3 (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C.
Amanzada A; Reinhardt L; Fey D; Zeisberg EM; Mihm S
PLoS One; 2015; 10(11):e0143783. PubMed ID: 26606750
[TBL] [Abstract][Full Text] [Related]
15. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
Matsuura K; Watanabe T; Tanaka Y
J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment.
Riva E; Scagnolari C; Turriziani O; Antonelli G
Clin Microbiol Infect; 2014 Dec; 20(12):1237-45. PubMed ID: 25273834
[TBL] [Abstract][Full Text] [Related]
17. Effect of interferon λ3 gene polymorphisms, rs8099917 and rs12979860, on response to hepatitis B virus vaccination and hepatitis B or C virus infections among hemodialysis patients.
Grzegorzewska AE; Jodłowska E; Mostowska A; Jagodziński P
Pol Arch Med Wewn; 2015; 125(12):894-902. PubMed ID: 26658164
[TBL] [Abstract][Full Text] [Related]
18. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
19. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
Holmes JA; Congiu M; Bonanzinga S; Sandhu MK; Kia YH; Bell SJ; Nguyen T; Iser DM; Visvanathan K; Sievert W; Bowden DS; Desmond PV; Thompson AJ
Aliment Pharmacol Ther; 2015 Aug; 42(3):296-306. PubMed ID: 26032235
[TBL] [Abstract][Full Text] [Related]
20. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
Aoki Y; Sugiyama M; Murata K; Yoshio S; Kurosaki M; Hashimoto S; Yatsuhashi H; Nomura H; Kang JH; Takeda T; Naito S; Kimura T; Yamagiwa Y; Korenaga M; Imamura M; Masaki N; Izumi N; Kage M; Mizokami M; Kanto T
J Gastroenterol; 2015 Aug; 50(8):894-902. PubMed ID: 25501286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
